BRIEF published on 11/26/2025 at 00:51, 7 months 1 day ago CureVac annonce les résultats de son assemblée générale extraordinaire Assemblée Générale Extraordinaire BioNTech Approbation Des Actionnaires CureVac Fusion Légale
BRIEF published on 11/26/2025 at 00:51, 7 months 1 day ago CureVac Announces Results of Extraordinary General Meeting BioNTech Extraordinary General Meeting CureVac Shareholders Approval Legal Merger
PRESS RELEASE published on 11/26/2025 at 00:46, 7 months 1 day ago CureVac Announces Voting Results of Extraordinary General Meeting CureVac announces approval of BioNTech's exchange offer for outstanding shares at Extraordinary General Meeting with over 99.16% approval rate BioNTech MRNA Technology Exchange Offer CureVac EGM Voting Results
BRIEF published on 11/24/2025 at 13:15, 7 months 2 days ago CureVac publie ses résultats financiers du troisième trimestre et des neuf premiers mois de 2025 Performance Financière CureVac Technologie De L'ARNm Résultats Du Troisième Trimestre 2025 Fusion BioNTech
BRIEF published on 11/24/2025 at 13:15, 7 months 2 days ago CureVac Reports Q3 and Nine-Month Financial Results for 2025 Financial Performance MRNA Technology CureVac Q3 2025 Results BioNTech Merger
PRESS RELEASE published on 11/24/2025 at 13:10, 7 months 2 days ago CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates CureVac announces financial results for Q3 and first nine months of 2025, BioNTech transaction progresses, EMA clearance received for cancer therapy CVHNLC sqNSCLC Financial Results Cancer Therapy CureVac BioNTech Transaction EMA Clearance
BRIEF published on 08/15/2025 at 13:32, 10 months 11 days ago CureVac Reports Q2 and H1 2025 Financial Results; Announces Key Developments Financial Results MRNA Technology CureVac Patent Resolution BioNTech Acquisition
BRIEF published on 08/15/2025 at 13:32, 10 months 11 days ago CureVac publie ses résultats financiers du deuxième trimestre et du premier semestre 2025 et annonce des développements clés Résultats Financiers CureVac Technologie De L'ARNm Résolution De Brevet Acquisition De BioNTech
PRESS RELEASE published on 08/15/2025 at 13:27, 10 months 11 days ago CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates CureVac announces Q2 2025 financial results, business updates & agreement with BioNTech for transformative mRNA treatments. Strong cash position Financial Results BioNTech CureVac MRNA Q2 2025
BRIEF published on 08/08/2025 at 02:20, 10 months 19 days ago CureVac Settles Patent Dispute with Pfizer/BioNTech MRNA Technology CureVac Pfizer/BioNTech Patent Resolution Vaccine Royalties
Published on 06/27/2026 at 01:40, 5 hours 46 minutes ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 7 hours 26 minutes ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 8 hours 26 minutes ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 8 hours 36 minutes ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/26/2026 at 22:15, 9 hours 11 minutes ago Revive Therapeutics Announces Proposed Private Placement
Published on 06/27/2026 at 00:05, 7 hours 21 minutes ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 7 hours 22 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 7 hours 50 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 7 hours 50 minutes ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 7 hours 59 minutes ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
Published on 06/26/2026 at 17:45, 13 hours 41 minutes ago Descriptif du programme de rachat d'actions
